574 related articles for article (PubMed ID: 19207660)
1. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
[No Abstract] [Full Text] [Related]
2. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
3. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
4. Psoriatic arthritis patients doing better on infliximab than etanercept.
Smith N; Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
[No Abstract] [Full Text] [Related]
5. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
6. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
Mikhail M; Weinberg JM; Smith BL
Arch Dermatol; 2008 Apr; 144(4):453-6. PubMed ID: 18427038
[No Abstract] [Full Text] [Related]
7. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
[No Abstract] [Full Text] [Related]
8. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
9. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
[No Abstract] [Full Text] [Related]
10. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
11. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].
Mrowietz U; Barth J; Boehncke WH; Rosenbach T; Wozel G
J Dtsch Dermatol Ges; 2005 Jun; 3(6):470-2. PubMed ID: 15892851
[No Abstract] [Full Text] [Related]
15. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
[TBL] [Abstract][Full Text] [Related]
16. TNF-alpha antagonists: pulmonary legionellosis.
Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
[TBL] [Abstract][Full Text] [Related]
17. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
[TBL] [Abstract][Full Text] [Related]
18. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
19. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.
Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
Scand J Rheumatol; 2011 Mar; 40(2):150-2. PubMed ID: 20868307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
